Study S002262

A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT03158805
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 60
Start: 2017-04-26
Primary completion: 2022-10-11
Lead sponsor: Lindner Center of HOPE
Conditions: Bipolar Disorder; Obesity
Interventions: DRUG:LIRAGLUTIDE; OTHER:Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Percent Change in Body Weight [40 week]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019781	Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. McElroy SL, Journal of clinical psychopharmacology	2024	Randomized trial	PMID 38227621 DOI	cites ClinicalTrials.gov:NCT03158805; registry reference DERIVED:38227621